0001562180-24-002298.txt : 20240305
0001562180-24-002298.hdr.sgml : 20240305
20240305170901
ACCESSION NUMBER: 0001562180-24-002298
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yarkadas Hayati
CENTRAL INDEX KEY: 0001657363
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35229
FILM NUMBER: 24722139
MAIL ADDRESS:
STREET 1: C/O TRINSEO S.A.
STREET 2: 1000 CHESTERBROOK BOULEVARD, SUITE 300
CITY: BERWYN
STATE: PA
ZIP: 19312
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xylem Inc.
CENTRAL INDEX KEY: 0001524472
STANDARD INDUSTRIAL CLASSIFICATION: PUMPS & PUMPING EQUIPMENT [3561]
ORGANIZATION NAME: 06 Technology
IRS NUMBER: 452080495
STATE OF INCORPORATION: IN
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 WATER STREET SE
CITY: WASHINGTON
STATE: DC
ZIP: 20003
BUSINESS PHONE: 202-869-9150
MAIL ADDRESS:
STREET 1: 301 WATER STREET SE
CITY: WASHINGTON
STATE: DC
ZIP: 20003
FORMER COMPANY:
FORMER CONFORMED NAME: ITT WCO, Inc.
DATE OF NAME CHANGE: 20110628
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-03-01
false
0001524472
Xylem Inc.
XYL
0001657363
Yarkadas Hayati
C/O XYLEM INC.
301 WATER ST SE
WASHINGTON
DC
20003
false
true
false
false
SVP & President, EU, WI & GLS
false
Common Stock
2024-03-01
4
A
false
7084.00
127.94
A
19198.00
D
Common Stock
2024-03-01
4
F
false
428.00
127.94
D
18770.00
D
Common Stock
2024-03-01
4
M
false
9698.00
102.23
A
28468.00
D
Common Stock
2024-03-01
4
S
false
9698.00
127.14
D
18770.00
D
Common Stock
2024-03-01
4
M
false
5035.00
86.76
A
23805.00
D
Common Stock
2024-03-01
4
S
false
5035.00
127.14
D
18770.00
D
Common Stock
2024-03-01
4
S
false
4870.00
127.14
D
13900.00
D
Common Stock
2024-03-01
4
M
false
4875.00
101.09
A
18775.00
D
Common Stock
2024-03-01
4
S
false
4875.00
127.17
D
13900.00
D
Common Stock
2024-03-05
4
S
false
4547.00
127.53
D
9353.00
D
Non-Qualified Stock Option (Right to Buy)
102.23
2024-03-01
4
M
false
9698.00
0.00
D
2031-03-01
Common Stock
9698.00
0.00
D
Non-Qualified Stock Option (Right to Buy)
101.09
2024-03-01
4
M
false
4875.00
0.00
D
2033-03-01
Common Stock
4875.00
9750.00
D
Non-Qualified Stock Option (Right to Buy)
86.76
2024-03-01
4
M
false
5035.00
0.00
D
2032-03-01
Common Stock
5035.00
5036.00
D
Stock Options (Right to buy)
127.94
2024-03-01
4
A
false
7932.00
127.94
A
2034-03-01
Common Stock
7932.00
7932.00
D
Reflects the acquisition of 4,739 shares of common stock upon vesting of performance-based stock units granted on March 1, 2021 under the Xylem Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to ROIC (2,934) and Total Shareholder Return (1,805). Reflects an award of 2,345 restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24, 2016) that are scheduled to vest in one third increments on March 1, 2025, March 1, 2026 and March 1, 2027.
Includes additional shares due to dividend reinvestment.
Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of performance-based stock units granted on March 1, 2021 (252) under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24, 2016). Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of restricted stock units granted on March 1, 2021 (39), March 1, 2022 (62), and March 1, 2023 (75) under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016).
This price represents the weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"). These Shares were executed at a range of prices from $127.03 to $127.30. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price.
This price represents the weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"). These Shares were executed at a range of prices from $127.10 to $127.55. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price.
The March 1, 2021 option grant vested 3,201 options on March 1, 2022, 3,265 options on March 1,2023, and 3,232 options on March 1, 2024.
The March 1, 2023 option grant vested 4,875 options on March 1, 2024, and will vest 4,875 options on March 1, 2025, and 4,875 options on March 1, 2026.
The March 1, 2022 option grant vested 5,035 options on March 1, 2023, 5,035 options on March 1, 2024, and will vest 5,036 options on March 1, 2025.
Reflects an award of non-qualified stock options pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one-third increments on March 1, 2025, March 1, 2026 and March 1, 2027.
/s/ Seaneen Cline, by power of attorney for Hayati Yarkadas
2024-03-05
EX-24
2
yarkadas_poa.txt
NOV 2023 POA
POWER OF ATTORNEY
The undersigned, Hayati Yarkadas, does hereby nominate constitute and
appoint each of Kelly O'Shea, Juliene Patton, Callie Plant, Seaneen Cline and
Dorothy Capers as his/her/their true and lawful attorneys and agents to do any
and all acts and things and execute and file any and all instruments which said
attorneys and agents may deem necessary or advisable to enable the
undersigned (in his/her/their individual capacity or in any other capacity) to
comply with the Securities Exchange Act of 1934 (the "34 Act") and the
Securities Act of 1933 (the "33 Act") and any requirements of the Securities and
Exchange Commission (the "SEC") in respect thereof, in connection with the
preparation, execution and/or filing of (i) any report or statement of
beneficial ownership or changes in beneficial ownership of securities of Xylem
Inc., an Indiana corporation (the "Company"), that the undersigned (in his/her/
their individual capacity or in any other capacity) may be required to file
pursuant to Section 16(a) of the 34 Act, including any report or statement on
Form 3, Form 4 or Form 5, or to any amendment thereto, (ii) any report or notice
required under Rule 144 of the 33 Act, including Form 144, or any amendment
thereto relating to the undersigned's role with, or beneficial ownership of, the
Company's securities, and (iii) any and all other documents or instruments that
may be necessary or desirable in connection with or in furtherance of any of the
foregoing, including Form ID, or any amendments thereto, and any other
documents necessary or appropriate to obtain codes and passwords enabling
the undersigned to make electronic filings with the SEC of reports required
pursuant to Section 16(a) of the 34 Act or any rule or regulation of the SEC,
such power and authority to extend to any form or forms adopted by the SEC
in lieu of or in addition to any of the foregoing and to include full power and
authority to sign the undersigned's name in his/her/their individual capacity
or otherwise, hereby ratifying and confirming all that said attorneys and agents
or any of them, shall do or cause to be done by virtue thereof.
This authorization shall supersede all prior authorizations to act for the
undersigned with respect to securities of the Company in such matters, which
prior authorizations are hereby revoked, and shall remain in effect until the
undersigned is no longer required to file Form 3, 4 or 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company
unless earlier revoked, by the undersigned in a signed writing delivered to the
foregoing attorneys in fact.
IN WITNESS WHEREOF, I have hereunto set my hand this 8th day of November 2023.
_____________________________
/s/ Hayati Yarkadas